
A Cure in Sight
The Triangle
A Cure In Sight™ (ACIS) exists to support people facing Ocular Melanoma (OM), also called Uveal Melanoma, the most common primary eye cancer in adults. Although OM affects a small patient population, with only about 3,000 new diagnoses in the U.S. and 7,000 worldwide each year, its rarity creates significant challenges in research, treatment options, and patient support. Ocular Melanoma carries a serious prognosis. About half of all OM patients will experience metastasis, and once the cancer spreads, outcomes remain extremely limited. No cure currently exists for metastatic OM. Still, new therapies, targeted treatments, and clinical trials offer growing hope. Advancing these options depends on research, yet research funding for rare cancers remains critically low. Grants are scarce and highly competitive, so ACIS relies on private and corporate donations to sustain programs and drive progress. A Cure In Sight provides nationwide support by raising public awareness, educating patients and caregivers, funding essential OM research, and offering financial assistance to patients seeking treatment. Continued funding ensures that we can expand these services and respond to the urgent needs of the OM community.
Programs
- Insight Biobank
- Insight Registry
- A joinpoint and age–period–cohort analysis of ocular cancer secular trends in Iran from 2004 to 2016
acureinsight.org
Your organization on Collective
Collective already keeps the Profile and the Wiki for A Cure in Sight. If you work there, join its team to run them, and Collective starts finding the people your work needs.



